Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Surgery 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Ductal Adenocarcinoma 1 Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1 Multiple Myeloma 1 Medulloblastoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 HER2-positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms 1 Breast Cancer Invasive 1

Interventions

Dexamethasone 46 Lenalidomide 30 Bortezomib 24 daratumumab 23 pomalidomide 20 Cyclophosphamide 16 carfilzomib 15 Specimen Handling 14 Biopsy 14 Calcium Dobesilate 12 isatuximab 11 Magnetic Resonance Spectroscopy 10 talquetamab 9 Melphalan 8 iberdomide 7 fludarabine 7 belantamab mafodotin 6 tocilizumab 5 selinexor 5 dexamethasone acetate 5 dexamethasone 21-phosphate 5 auricularum 5 X-Rays 5 fludarabine phosphate 4 elotuzumab 4 Sirolimus 4 Nuclear Medicine Department, Hospital 4 trametinib 3 dabrafenib 3 Whole-Body Irradiation 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Neoadjuvant Therapy × 30 days × Clear all

NCT07149857 2026-06-05

CARTITUDE-10

Janssen Research & Development, LLC

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡